Browse By Publication: Current Opinion in Investigational Drugs

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: No Grouping | Volume | Authors/Creators
Number of items: 8.

Doggrell, Sheila (2005) BG-9928 (Biogen Idec). Current Opinion in Investigational Drugs, 6(9), pp. 962-968.
Number of citations in Scopus 9

Doggrell, Sheila (2006) Bradykinin B2 receptors as a target in diabetic nephropathy. Current Opinion in Investigational Drugs, 7(3), pp. 251-255.
Number of citations in Scopus 4
Number of citations in Web of Science® 7

Doggrell, Sheila (2007) Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target? Current Opinion in Investigational Drugs, 8(9), pp. 742-749.
Number of citations in Scopus 8
Number of citations in Web of Science® 5

Doggrell, Sheila (2005) Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. Current Opinion in Investigational Drugs, 6(9), pp. 874-878.
Number of citations in Scopus 11

Doggrell, Sheila (2005) Conivaptan (Yamanouchi). Current Opinion in Investigational Drugs, 6(3), pp. 317-326.
Number of citations in Scopus 7

Doggrell, Sheila (2006) New targets in and potential treatments for cholesterol gallstone disease. Current Opinion in Investigational Drugs, 7(4), pp. 344-348.
Number of citations in Scopus 8
Number of citations in Web of Science® 5

Doggrell, Sheila (2006) Nitrone spin on cerebral ischemia. Current Opinion in Investigational Drugs, 7(1), pp. 20-24.
Number of citations in Scopus 6
Number of citations in Web of Science® 5

Doggrell, Sheila (2005) Taking the 20-HETE out of the cardiovascular system: The potential of 20-HETE synthesis inhibitors. Current Opinion in Investigational Drugs, 6(9), pp. 901-906.
Number of citations in Scopus 2

This list was generated on Sun Apr 30 14:15:26 2017 AEST.